The topic of this article may not meet Wikipedia's general notability guideline. Please help to demonstrate the notability of the topic by citing reliable secondary sources that are independent of the topic and provide significant coverage of it beyond a mere trivial mention. If notability cannot be shown, the article is likely to be merged, redirected, or deleted.Find sources: "Avecia" – news · newspapers · books · scholar · JSTOR (September 2023) (Learn how and when to remove this message)
This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.Find sources: "Avecia" – news · newspapers · books · scholar · JSTOR (September 2023) (Learn how and when to remove this message)

Avecia, a part of Nitto Denko Inc., is a private biotechnology company focused on oligonucleotide production.[1] Avecia has two facilities, one near Boston, MA, and the second in Cincinnati, OH.[1] In 2016 Avecia acquired the assets of Irvine Pharmaceutical Services and Avrio Biopharmaceuticals.[2]

References

  1. ^ a b Kansteiner, Fraiser (March 31, 2021). "Nitto Denko lays out $226M to boost oligonucleotide production in a bustling RNA market". Fierce Pharma. Retrieved June 3, 2024.
  2. ^ "Nitto Denko Avecia Inc acquires businesses of Irvine Pharmaceutical Services, Avrio Biopharmaceuticals". Reuters. October 11, 2016. Retrieved June 3, 2024.

External links

Category